The prognosis of patients with allograft IgA nephropathy (IgAN) requires further investigation. We performed a bicenter retrospective cohort study on kidney transplant recipients diagnosed with IgAN in allograft biopsy. Recipients without allograft IgAN but with known IgAN before transplantation were included as the control group. We investigated the associations between clinicopathological characteristics, including allograft crescents, and the risk of death-censored graft failure. In total, 1256 IgAN patients in both pre-and posttransplant stages were included. Among them, 559 were diagnosed with allograft IgAN, which was a time-dependent risk factor for worse prognosis (adjusted hazard ratio = 5.009 [3.610-6.951]; P < .001) during a median of 8.1 years of follow-up. Of the patients with allograft IgAN, 88 (15.9%) had glomerular crescents, including 40 patients (7.2%) with >10% crescent formation in the total biopsied glomeruli. The presence of glomerular crescents in IgAN was associated with a worse graft prognosis, and the association was still valid with the C scores of the current Oxford classification. In conclusion, allograft IgAN is a timedependent event and is associated with worse graft outcomes. The pathological characteristics of allograft, particularly the degree of glomerular crescent formation, may represent important risk factors for a poor prognosis.
| INTRODUC TI ON
Recurrent glomerulonephritis is an important cause of graft failure after kidney transplantation. 1 IgA nephropathy (IgAN), one of the most prevalent forms of primary glomerulonephritis worldwide, represents a substantial burden to end-stage renal disease (ESRD). 2, 3 As IgAN patients receive transplantation at a relatively young age with few comorbidities, they have a better transplant outcome than do those with other causes of ESRD. 4 On the other hand, this raises the importance of considering the long-term prognosis for IgAN. In this respect, recurrent IgAN represents a critical issue, as the recurrence of IgAN adversely affects transplantation outcome. 4, 5 Several risk factors have been reported for IgAN recurrence, although a general consensus has yet to be established. In addition, the prognosis of posttransplantation IgAN with uncertain primary disease, which clinicians may commonly encounter during practice, requires further investigation.
Pathologic findings in native kidney biopsy of IgAN have a significant prognostic value. Previous studies have described useful scoring criteria, known as MEST scores or the Oxford Classification, for IgAN, which have become widely adopted in clinical practice. 6 More recent research has highlighted the importance of crescent formation in native IgAN pathology; as a result of these findings, the original scoring system was updated to become the MEST-C scoring system. 7 However, although the clinical significance of MEST scoring for allograft IgAN has been demonstrated, 8 there is only limited knowledge as to whether crescent formation in allograft IgAN bears prognostic information.
Previous studies have reported rapid deterioration of graft function in crescentic allograft IgAN; however, the number of cases in these studies was small and additional robust comparison with a control group was warranted. 9, 10 In the present study, we investigated a large number of patients diagnosed with allograft IgAN in order to assess the risk factors and clinical impact of this disease. In addition, we collated a range of clinical and pathological parameters at the time of posttransplantation IgAN diagnosis that were used to evaluate the clinical association between glomerular crescents in allograft IgAN patients and deathcensored graft failure (DCGF).
| ME THODS

| Ethical considerations
The institutional review board (IRB) of Seoul National University 
| Study design and study population
This was a retrospective cohort study carried out in 2 tertiary teaching hospitals in Korea: SNUH and AMC. Patients with confirmation The clinical characteristics were collected upon the time of renal transplantation. Missing values were present in the donor age (n = 5), donor sex (n = 3), HLA mismatch (n = 219), ABO incompatibility (n = 196), and medication usage history (n = 2). ATG, antithymoglobulin; RRT, renal replacement therapy; TPL, transplantation.
of IgAN in their allograft biopsies (allograft IgAN) were included in the study group. Patients who had biopsy-proven IgAN as an initial cause of ESRD, but confirmed to be devoid of recurrent IgAN, were included in the control group. Patients who had multiorgan transplantations were not considered.
| Allograft IgAN and graft biopsy
Allograft IgAN following kidney transplantation was pathologically confirmed by graft biopsy. We performed allograft biopsies in cases showing a progressive decline in renal function, persistent hematuria, or significant proteinuria of more than 1.0 g/day. 5 Routine protocol biopsy was not always performed, although some of the transplant recipients underwent biopsy at time zero and then again 2 weeks after transplantation. Biopsied tissues were examined using light, electron, and immunofluorescence microscopy by experienced hospital pathologists. The pathological diagnosis of allograft IgAN was made when the biopsied tissue specimens showed a typical immunofluorescence pattern of IgA ± C3 dominant staining in the glomerulus mesangial space. Other pathological characteristics were also investigated in the kidney allografts and used for the diagnosis of allograft IgAN. For example, the degree of pathological change in the glomeruli was classified as none, mild to moderate, or severe.
Cutoff values were as follows: global sclerosis (0, >0% and ≤40%, >40%), segmental sclerosis (0, >% and ≤20%, >20%), and crescent formation (0, >0% and ≤10%, and >10%). Only the cellular or fibrocellular crescents were included in the study, as suggested by the Oxford classification. 7 The main cutoff value for the degree of crescent formation was defined in order to distribute the number of patients with the findings similarly between the >0% and ≤10%, and >10% subgroups, as the number of patients with a high degree of crescents was small. We also performed an analysis using the C and S scores suggested in the MEST-C scoring system. 7, 11 Coexisting evidence of acute rejection was also collated. In SNUH, allograft pathology was additionally reviewed for this study, and MEST scores were recorded in accordance with the Oxford classification. 6 This practice, however, was not performed in AMC.
| Data collection
The following baseline demographic data were collected for the entire study population at the time of renal transplantation: age, sex, and body mass index (BMI). Baseline history of hypertension and diabetes mellitus was also recorded, as was the type of renal replacement therapy prior to transplantation. We also collated information relating to donor age, sex, whether the donor was cadaveric or not, the relationship of the donor to the recipient, the presence/absence of ABO mismatch and the number of HLA antigen mismatches. We also obtained information on the use of immunosuppressive agents including cyclosporine, tacrolimus, mycophenolate mofetil or sodium, azathioprine, and maintenance steroids and on whether immunosuppressive induction therapy, including the use of basiliximab or antithymocyte globulin, had been performed. Peritransplantation medication history was recorded until 6 months after transplantation, and the use of medications was reviewed for the same duration before and after the diagnosis of allograft IgAN.
We recorded the following characteristics at the time of biopsy in patients diagnosed with 
| Clinical outcomes
The main clinical outcome was death-censored-graft failure (DCGF).
Irreversible graft failure was defined as a return to long-term dialysis (or retransplantation), and events of death with a functioning graft were censored. When investigating the prognosis of patients with allograft IgAN, we recalculated survival duration from the date of the diagnosis of allograft IgAN.
| Statistical analysis
Categorical variables are presented herein as frequencies and per- Values were missing for donor age (n = 5), donor sex (n = 3), the number of HLA mismatches (n = 219), ABO incompatibility (n = 196) and the history of medication usage (n = 2). As missing values tended to appear in a random manner, such data underwent multivariate imputation by classification and the regression trees method with "mice" package in R (version 3.4.2, The R Foundation). 13 All other statistical analyses were also performed with R. A 2-sided P < .05 was considered to indicate statistical significance.
| RE SULTS
| Study population
We identified 1258 kidney transplant recipients with pre-or post- The analysis was done within those who had unknown or other initial diagnosis than IgAN (n = 439). f The analysis was done excluding the allograft IgAN cases who were diagnosed within 2 weeks from the transplantation (n = 46), as donor origin IgAN was possible. The analysis was done excluding the patients who did not receive allograft biopsy (n = 366), as hidden IgAN was possible and the excluded patients had relatively stable posttransplant clinical course. Table 1 shows the baseline characteristics of the study population according to the presence of allograft IgAN. Patients with allograft IgAN tended to be younger in age (P < .001) and were more frequently male (P < .001). The study group received transplantation in an earlier era (P < .001) and cyclosporine was more commonly used (P < .001)
TA B L
E 4 Characteristics of the patients with allograft IgAN according to crescent proportion
| Baseline characteristics
as the maintenance immunosuppressants. In contrast, tacrolimus (P < .001) and mycophenolic acid (P < .001) were less commonly prescribed in the patients with allograft IgAN. In addition, allograft
IgAN occurred in a time-dependent manner with a median time to diagnosis of 4.4 years ( Figure S1 ). Donor type (P = .986), donor sex (P = .622), and the use of maintenance steroid treatment (P = .395)
were not significantly different when compared between the study and the control group.
| Risk factors for allograft IgAN
Age of recipient or donor, donor relationship, HLA mismatch, ABO incompatibility, or peritransplant immunosuppression medications were not significantly associated with the risk of allograft IgAN ( Table 2) . We also assessed specific recipient HLA types (A2, B35, DR4, or zero mismatch) that were considered in previous studies 5,14-16 but could not identify significant association.
On the other hand, when the recipient was male and the donor was female, the risk of allograft IgAN was significantly increased (Table S1 ). Within this group of patients, none of the clinical characteristics that we investigated were associated with the risk of allograft IgAN including the particular sex relation.
| Prognosis of allograft IgAN
The 5-year and 10-year graft survival of the study population was 804/829 (97.0%) and 451/518 (87.1%), respectively. The patient graft failure rate for allograft IgAN appeared to be similar to that for the control group during the early posttransplantation period but worsened over time from 7 to 8 years after transplantation ( Figure 1 ). The median time to DCGF, when occurred, from the diagnosis of allograft IgAN was 3.1 (1.4-6.8) years. In our multivariable model (Table 3 
| Clinicopathological characteristics of allograft IgAN patients with crescent formation
The clinicopathological characteristics of allograft IgAN patients, according to crescent formation, is shown in Table 4 . Patients with a severe degree (>10%) of crescents had an older graft age 
| Crescent formation and DCGF in allograft IgAN
We performed multivariable analysis to identify prognostic factors for allograft IgAN ( Table 5) Next, we performed 4 sensitivity analyses, as described previously (Table 6 ). When the current Oxford classification criteria were implemented, both C1 (adjusted HR: 2.243; 95% CI: 1.526-3.297; P < .001) and C2 (adjusted HR: 4.306; 95% CI: 1.875-9.889; P < .001) were associated with an increased risk of DCGF in allograft IgAN. Also, S1 (adjusted HR: 2.030; 95% CI: 1.453-2.837; P < .001) was an independent predictor for an adverse outcome.
As there were few patients (n = 10 or n = 8 after excluding those with fewer than 8 biopsies) with such a high proportion of crescents (≥ 25%), further sensitivity analyses in the subgroups were performed with a cutoff value of 10%. The presences of glomerular crescents, both less or equal to 10% or above 10% were significant risk factor for worse allograft prognosis when studied patients were divided according to whether their initial cause of ESRD was proven IgAN. Moreover, the presence of crescents in > 10% of biopsied glomeruli remained significantly associated with graft outcome (adjusted HR: 13.324; 95% CI: 4.337-40.930; P < .001) even after simultaneously adjusted for the proportion of global sclerosis or segmental sclerosis, within the confirmed recurrent IgAN cases.
The global sclerosis and segmental sclerosis also showed substantial association with a worse graft outcome ( Figure S2 ). However, the statistical significance of those variables became weak or was lost in the sensitivity analysis.
In the SNUH cohort in which the information of MEST score was available, those with higher MEST scores had worse graft outcome, except for endocapillary hypercellularity as this parameter was not associated with DCGF in the cohort (Table S2 and Figure S3 ).
| D ISCUSS I ON
Our present study showed that allograft IgAN was predominantly a time-dependent event and was associated with a significantly higher With those who had known initial diagnosis as IgAN (n = 120), degree of 3 pathologic parameters, crescent formation (categorical, 0%, >0% and ≤ 10%, >10%), global sclerosis (categorical, 0%, > 0% and ≤40%, > 40%) and segmental sclerosis (categorical, 0%, >0% and ≤20%, >20%) were simultaneously added to the multivariable model.
IgAN would be helpful for clinical practice. In the present study, we demonstrated that allograft IgAN is a significant risk factor for poor graft outcome, and additional risk factors for a worse prognosis within allograft IgAN were investigated. A particular strength of our study is that we included, to the best of our knowledge, the largest number of allograft IgAN patients evaluated so far and used this cohort to assess the prognostic importance of graft pathology. 9, 10 In our present study, we showed that cellular or fibrocellular crescents in allograft IgAN were associated with a worse posttransplant outcome, and this was also true with the Oxford criteria C scores. In addition, with the exception of endocapillary hyperfiltration, we showed that MEST scores were potentially associated with transplant prognosis. Therefore, components of the MEST-C scoring system may also represent an important predictor of the prognosis of allograft IgAN, and routine reporting and consideration of these pathological parameters may be warranted for posttransplantation biopsy.
18, 20
Previous studies have investigated a range of risk factors for posttransplantation IgAN. A young age, male sex, living related donor, steroid withdrawal, and specific HLA subtypes have all been previously reported as factors associated with the risk of recurrent IgAN, although a consistent consensus has yet to be established. 1, [21] [22] [23] In our study, the sex of the donor and the recipient, in cases where the recipient was male and the donor was female, was identified as a factor associated with the risk of allograft IgAN. However, this may be a biased result as this specific sex relation would be associated with poor graft function, which leads to a higher possibility of allograft biopsies. 24 The fact that the association was not reproduced within patients who received graft biopsies support our previous assertion.
Steroid withdrawal, which could hardly be assessed in our cohort as most of the patients maintained with steroids, younger recipient age, nor donor relation showed association with the risk of allograft IgAN.
Still, we could see that allograft IgAN was strongly a time-dependent event.
Our study also showed that allograft IgAN was associated with an increased risk of DCGF. During the first 10 years from transplantation, the renal survival between the allograft IgAN patients and the controls seemed similar. 25 However, as allograft IgAN occurred in a time-dependent manner, the worse prognosis in allograft IgAN became prominent over time. Interestingly, patients who had known Our study has several limitations that need to be considered.
First, we did not include pathological findings from native graft biopsies because such data were frequently unavailable. Consequently, it was not possible to investigate the link between posttransplant prognosis and pathological parameters in native IgAN herein.
Second, the definitive separation of de novo IgAN and recurrent
IgAN was not possible in our study. Yet, we believe that clinicians will encounter a mixture of de novo and recurrent IgAN cases and we therefore included data from all of our allograft IgAN patients.
In addition, our sensitivity analysis revealed the importance of allograft crescents in patients with recurrent IgAN. Third, because of the nature of our retrospective study, it is possible that hidden confounding variables may exist. This also was a reason that we could not investigate possible treatment strategy for allograft IgAN. Lastly, clinical management or pathological diagnostics were not standardized between the 2 study hospitals. In addition, transplantations in the past period were included in our analysis, and it was therefore inevitable that allograft IgAN was mostly diagnosed after a long duration of follow-up.
In conclusion, allograft IgAN was shown to be a time-dependent event and was significantly associated with a worse posttransplant prognosis. In particular, allograft crescents may represent important predictive parameters for the outcome of posttransplantation IgAN. Pathological parameters associated with allograft IgAN should therefore be carefully interpreted and reported in order to identify patients at risk of a poor prognosis. 
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